Market Overview

OTC Stock Picks Newsletter Up 90% on Penny Stock EKO International

Share: Newsletter Announces 90% Gains on Top Healthcare Penny Stock EKO International Corp, and Thoughts For Investors

Stamford, CT (PRWEB) October 26, 2012

OTC Stock Picks is a premier penny stock newsletter focused on bringing investors the next great trading opportunity. The OTC Stock Picks team has been following EKO International (EKO) since $0.05, and alerted the company from the $0.40 range, and we are excited where EKO is headed in the near future!

EKO investors saw nearly 20% gains in the first 2 trading sessions this week. The Friday close for EKO shares was $0.62, and shares peaked at $0.76 this past Tuesday, giving the OTC Stock Picks team and subscribers a whopping 90% overall gain.

Shares rallied early this week after a Monday release from EKO announcing that MaloneBailey LLP, Certified Public Accounting Firm has been appointed as auditors of the Company. MaloneBailey is a market leader in the delivery of SEC audit services to small and mid-cap publicly traded clients, with over 100 U.S. listed public companies as clients, including NYSE, NASDAQ and AMEX listed companies.

This announcement comes on the heels of the October 15 release from EKO announcing that it has initiated the process of reducing the number of authorized common shares of the Company, from One Billion (1,000,000,000) to Seventy Five Million (75,000,000), and will initiate a share buy-back program upon reaching a positive income statement.

These combined releases glaringly suggest to the investment community that EKO management is committed to turning a profit at some point during the business cycle, and up-listing to a higher exchange, a feat that requires a $2.00 minimum per share price.

The ‘other' main focus for investors of EKO International, of course, is product NC-Stat DPN, currently being utilized by doctors and patients in Wal-Mart Canada clinics and managed care organizations in the US, for assisting in detecting Diabetic Peripheral Neuropathies (DPN).

NC-Stat DPN is a MUCH needed product in a HUGE market! The annual cost of DPN has been estimated at $14 billion in the United States, where there are roughly 25 million diabetics.

Starting today, EKO's joint venture partner on NC-Stat DPN, NeuroVasc Clinical Inc. (NCI), will be joining over 50 exhibitors at the Canadian Federation of Podiatric Medicine 13th Annual Conference in London, Ontario (October 26th and 27th, 2012) presenting FREMS (Frequency Rhythmic Electrical Modulation System) devices (used to treat DPN). Events such as this are custom-made for landing potential deals and contracts, as company leaders meet in person.

The OTC Stock Picks team wants to emphasize to investors, that EKO International is truly and up and coming company, with a much needed product in the marketplace, and is making all the right moves to attract investors.

As sales numbers and interest in NC-Stat DPN grow, and as share reduction and ‘march' toward higher exchange status continues, the OTC Stock Picks team feels that a $2.00 per share price is a real possibility, leaving our 90% gains of Tuesday in the dust!

About OTC Stock Picks

The team is among the US market leaders in connecting penny stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse' of the penny stock market.

The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter.

The company also offers investors Free Level II service and Free Real Time Stock Charts on its company website.

Disclaimer: OTC Stock Picks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Please visit for a more complete list of risks and disclosures.

For the original version on PRWeb visit:

View Comments and Join the Discussion!